Lead your paid marketing with PRP. Keep stem cell in the funnel, not at the front of it. Autologous PRP generally clears FDA's lower-bar 361 pathway and clears Google and Meta ad review far more easily. Stem cell products, especially culture-expanded or allogeneic ones, almost always require FDA approval clinics don't have, and FDA has been issuing warning letters to stem cell clinics roughly monthly through 2026.
This isn't a workaround. It's the actual regulatory shape of the category: PRP and stem cell are treated identically under FTC's truthfulness rules, but completely differently under FDA's product rules. Build the funnel around that fact instead of around what reads best in an ad. Our full regenerative medicine marketing page covers the whole channel mix if PRP-vs-stem-cell is one part of a bigger build for you.
The fast verdictPRP for capture. Stem cell for education, not acquisition.
Every regenerative medicine founder asks some version of the same question: "Our stem cell offering is the more impressive treatment, so why would we lead marketing with PRP instead?" It's a fair instinct; stem cell therapy is the higher price point, the more advanced-sounding procedure, and often the thing that made the founder want to open the clinic in the first place. But what's impressive clinically is not the same as what's advertisable, and confusing the two is what gets clinics a warning letter.
PRP & Orthobiologics
Autologous, minimally-manipulated, your own blood, your own tissue.
- Lower regulatory bar. Unmodified, same-procedure autologous PRP generally sits inside FDA's 361 exemption pathway.
- Clears ad review more easily. Not named on Google's speculative/experimental treatment prohibited list.
- Mechanism-based claims are straightforward. "Concentrates your own platelets to support the body's healing response" is a factual procedure description, not a disease-outcome promise.
- Familiar to more patients. Orthopedic and sports-medicine PRP has been mainstream for over a decade.
- Faster consultation-to-treatment cycle since there's less candidacy screening friction than stem cell.
So which is "better"? Wrong question again, same as the last comparison we ran on this exact template. The right question is which one your paid acquisition can legally and safely carry, versus which one belongs deeper in the funnel where you have room to explain it properly. PRP does the first job. Stem cell does the second.
"May help with" is not a safe harbor. FTC's 2022 Health Products Compliance Guidance explicitly says qualifiers like "may" or "helps" do not cure a claim built on limited or emerging science, especially anything disease-related. If you don't have competent and reliable scientific evidence behind a claim (RCT-level, for disease-related claims), softening the verb doesn't fix it. The fix is not making the disease-outcome claim at all, for either PRP or stem cell copy.
The exact playbookHow PRP and stem cell each move through the funnel
High-intent capture
Discovery + video
Blog, FAQ, AI search
Where the real conversation happens
Notice what this structure actually does: it lets a clinic market both service lines honestly without ever making the promotional claim that gets flagged. PRP earns the click. The consultation earns the stem cell conversation. Nothing in paid media promises an outcome for either one. If you're also deciding which platform should carry that PRP budget, see our companion breakdown, Google Ads vs Meta Ads for Clinics, the channel logic there applies directly once PRP is your lead service.
Why PRP wins the front doorThe regulatory mechanics, in plain English
Stem cell and PRP products are both regulated as Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) under 21 CFR Part 1271, but they fork hard once you look at how each is typically prepared and used.
"361 products" (the lower bar, where autologous PRP usually lives)
Minimally manipulated, homologous use, autologous or same-family, not combined with another article, no more than minimal systemic effect. Unmodified autologous PRP, drawn from the patient and re-injected the same day under the "same surgical procedure" exception, generally clears this bar without needing premarket FDA approval.
"351 products" (the high bar, where most clinic stem cell offerings live)
Culture-expanded or allogeneic mesenchymal stem cells, umbilical cord or amniotic-derived products marketed for systemic or non-homologous use, and exosomes are regulated as drugs or biologics requiring an IND and a BLA before marketing. Almost none of the products sold by commercial stem cell clinics have this approval. This is exactly where FDA enforcement concentrates.
U.S. stem cell clinics tracked in 2021 versus 570 in 2016, per Turner's tracking published in Cell Stem Cell. The category grew nearly 5x in five years, and FDA's enforcement posture has grown with it: a February 2026 warning letter to Dynamic Stem Cell Therapy cited claims of treating knee, shoulder, ankle, and hip injuries, one of several similar letters sent to clinics nationally through Q1 2026.
What the ad platforms actually allowGoogle and Meta don't treat these two services the same
Google Ads
Since 2019, Google has banned ads for "speculative and/or experimental medical treatment," explicitly naming stem cell therapy as a prohibited example. A 2022 policy update eased this slightly: cell and gene therapy ads are now permitted in the U.S., but only for an entity holding the actual FDA license or approval for that specific product, applied for through Google's exception process. Purely educational content with no product promotion is allowed worldwide regardless of approval status. In practice, this means essentially all commercial stem cell promotional advertising stays banned on Google unless a clinic's exact product has FDA approval, which is rare to nonexistent for clinic-administered regenerative treatments. PRP does not carry this named prohibition and is evaluated under Google's general healthcare-claims policy instead.
Meta
Meta has no itemized prohibited list for stem cell therapy the way Google does. Its Health & Wellness ad standards broadly restrict health claims at Meta's discretion. What agencies report (not confirmed in Meta's own published policy text, and worth verifying with a live test ad before committing budget) is that Meta disapproves cure, reversal, or regeneration language case by case and has been known to block lower-funnel conversion tracking on stem-cell-adjacent ad accounts. Treat this as directional risk, not settled policy.
LegitScript is not the shortcut it is for addiction treatment
For addiction and substance-use-disorder treatment, LegitScript certification is an explicit, named prerequisite on both Meta and Google. For regenerative medicine and stem cell therapy, no equivalent named certification pathway exists. LegitScript's published healthcare categories (pharmacies, telemedicine, med spas, digital health, pharma manufacturers) don't list stem cell/regenerative medicine as its own bucket. Google's real gate for cell and gene therapy ads is proof of FDA license or approval for the specific product, not LegitScript status. Certification may still help general account standing, particularly if the clinic also runs med-spa-adjacent services, but it will not by itself unlock stem cell ad approval.
Not sure where PRP and stem cell fit in your funnel?
We built the free calculator for ad spend and LTV/CAC math, but the compliance structure question is one worth talking through live. 30 minutes, no pitch deck.
Open the LTV/CAC Calculator →What a compliant funnel actually looks likeNine things to get right before copy ships
1. Describe the procedure, not a disease outcome
"PRP concentrates platelets from your own blood, injected to support the body's natural healing response" is a mechanism statement. "Treats arthritis" is a disease-outcome claim. Only one of those is safe to run as an ad.
2. Never pair stem cell with a named condition
Arthritis, Parkinson's, autism, MS, COPD, ALS, heart disease, autoimmune conditions. This exact pattern is behind FDA's warning-letter wave and FTC's $3.31M 2018 judgment.
3. Lead with candidacy and credentials
Physician oversight, sterile processing protocols, informed consent, what a visit involves. Lower legal risk and more likely to pass ad-platform review than promised-results copy.
4. Substantiate any outcome statistic to the claim's level
Disease-related outcome stats need RCT-level evidence. An internal patient-satisfaction survey is not substitute substantiation for a clinical claim.
5. Use testimonials only with real backing
Show the featured result is typical, or disclose what the generally expected outcome is right alongside it. "Results not typical" alone does not satisfy FTC's standard. Disclose any compensation or comped treatment.
6. Scope any FDA reference precisely
If a processing kit or device is FDA-cleared, say that specifically about the device. Don't let copy imply the biologic or treatment itself is FDA-approved.
7. Post required state disclosures
California's SB 512 requires a specific notice, posted and given to patients before any non-FDA-approved stem cell therapy. Check the specific state(s) your clinic operates in; requirements vary.
8. Build paid media around education, not outcome
A consultation CTA is what's actually permitted under Google's current exception structure and more likely to clear Meta review than a treatment/outcome CTA.
9. Remember PRP and stem cell are equal under FTC, unequal under FDA
PRP has a meaningfully lower FDA bar when autologous and minimally manipulated. But Section 5 truthfulness and substantiation obligations apply identically to both, regardless of which product line a claim is about.
California Business & Professions Code (SB 512, 2018) requires any practitioner performing a non-FDA-approved stem cell therapy to post, and provide to patients before treatment, this exact notice: "This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care physician prior to undergoing a stem cell therapy." Fines run up to $1,000 per violation. This is a California-specific requirement confirmed directly; other states may have similar, different, or no equivalent rule, and a healthcare-advertising attorney should review the final funnel before it goes live, the same step we flag on every regenerative-medicine build.
Why use an agency for this at allThe math, and the compliance risk, of doing it yourself
Most regenerative medicine founders eventually ask whether they should just run this in-house. For most categories, the honest math already leans toward "not yet, the in-house cost is 4 to 14x the agency retainer for the same output." For this category specifically, there's a second reason that matters more: a generalist in-house hire or a generalist agency without healthcare-compliance depth is how clinics end up on FDA's warning-letter list. The skill that matters most here isn't creative talent, it's knowing exactly where the 361/351 line sits and writing every piece of copy on the correct side of it.
"The clinics that get warning letters aren't usually being reckless on purpose. They're running the same ad template that works for a med spa and applying it to a product line with a completely different regulatory ceiling. The fix isn't fewer ads. It's knowing which service goes in front of the camera and which one goes in the consultation room." Preston Durnford · Founder, Pelora Marketing
The shortlistBest marketing agencies for regenerative medicine clinics in Newport Beach & Orange County
If you're researching agencies for this specific category, here's how the field actually breaks down. We put ourselves at the top because that's what we believe, but we're including the others honestly because you should compare. Ask each one the same question: can you explain the difference between a 361 and a 351 product without looking it up? That answer tells you more than any pitch deck will.
Pelora MarketingOur pick
Operator-led, compliance-aware marketing agency for regenerative medicine and stem cell clinics in Newport Beach and OC. Founder built and exited two healthcare companies, scaled 20+ clinics across the region. In-house video production, CRM build-outs (GoHighLevel), and a funnel structure built around FDA's 361/351 distinction rather than a generic wellness template. peloramarketing.com
Operator-led
Cardinal Digital Marketing
National healthcare-focused agency with deep paid media expertise. Good for mid-sized multi-location regenerative medicine practices. Strong reporting infrastructure. Less personalization than a boutique. cardinaldigitalmarketing.com
Healthcare specialist
ClinicGrower
Healthcare-focused performance marketing agency known for med spa and wellness clinic acquisition campaigns. Pay-per-performance options available. Less operator depth on the regulatory side than a founder-built clinic background. clinicgrower.com
Performance-based
Practice Builders
National full-service healthcare agency with 40+ years in the medical marketing space. Strong on traditional channels (direct mail, print, broadcast). Less video-first or social-native, and less specialized in the stem cell/PRP regulatory nuance. practicebuilders.com
Full-service
WebFX
Massive national digital marketing agency with a healthcare practice area. Strong on SEO and paid media at scale. Less specialized in clinic operations, video production, or the FDA/FTC compliance detail this category needs. webfx.com
Large generalist
Note: Agency rankings are our opinion based on what we know of each. Pricing, capabilities, and compliance depth vary widely. Always book a discovery call with 2-3 agencies before signing, and ask each one directly how they handle FDA/FTC claim review before copy ships. Look for operator answers, not generic agency answers.
Let's see if we're the right fit.
Book a 30-minute strategy call. I'll walk through your service mix, what's safe to lead with in paid media right now, and exactly what would change in the first 90 days. No pitch deck. Just operator-to-operator strategy.
Book a Strategy Call → See the Full Regenerative Medicine PageFAQCommon questions
Should a regenerative medicine clinic lead its marketing with stem cell or PRP?
PRP, almost always. Autologous, minimally-manipulated PRP generally qualifies for FDA's 361 pathway and carries a much lower regulatory bar than culture-expanded or allogeneic stem cell products, most of which require an IND and BLA that clinics don't have. PRP also clears Google and Meta ad review far more easily. Stem cell therapy stays in your funnel, described mechanically and paired with candidacy and consultation language, but it should not be the hook in paid acquisition.
Can a clinic legally advertise stem cell therapy at all?
Yes, but narrowly. You can describe what the procedure is and how it works mechanically. What you cannot do is name a disease and promise an outcome (treats arthritis, reverses joint damage, cures autoimmune conditions) unless you hold FDA approval for that specific product, which almost no clinic-administered stem cell offering has. FDA issued warning letters to stem cell clinics on a roughly monthly cadence through 2026 for exactly this pattern.
Is "may help with" safe language for stem cell marketing?
No. This is the single most common compliance mistake. FTC's 2022 Health Products Compliance Guidance explicitly states that qualifiers like "may" or "helps" do not cure a claim resting on limited or emerging science, especially for anything disease-related. If you don't have competent and reliable scientific evidence (generally RCT-level for disease claims), softening the verb does not fix the underlying problem. The fix is not making the disease-outcome claim at all.
Will Google Ads or Meta approve stem cell therapy ads?
Google bans ads for speculative and experimental medical treatment, naming stem cell therapy explicitly, unless the advertiser holds actual FDA license or approval for that specific product, applied for through Google's exception process. Purely educational content with no product promotion is allowed. Meta has no itemized public policy naming stem cell therapy the way it names addiction treatment, but agencies report disapprovals and blocked conversion tracking on cure or reversal language, treated case by case. In practice, condition-based promotional ads for stem cell products get rejected on both platforms; educational, consultation-focused content tends to clear review.
Does LegitScript certification unlock stem cell advertising the way it does for addiction treatment?
No, and this is a common misunderstanding. For addiction treatment, LegitScript certification is an explicit, named prerequisite on both Meta and Google. For regenerative medicine and stem cell therapy, no equivalent named certification pathway exists. Google's actual gate is proof of FDA license or approval for the specific product, not LegitScript status. LegitScript may still help general account standing, and it matters if the clinic also runs med-spa-adjacent services, but it will not by itself unlock stem cell ad approval.
What does a compliant regenerative medicine marketing funnel actually look like?
Paid acquisition (Google and Meta) leads with PRP, orthobiologics, and general regenerative consultation content, described by mechanism and candidacy rather than promised outcome. Educational content, blog posts, and FAQ pages carry the stem cell information, again mechanism-first, no disease-specific promises, with any required state disclosure (California's SB 512 notice, for example) posted and reproduced in intake paperwork. Testimonials are used only when the featured result is typical or a clear disclosure of expected outcomes runs alongside it. The consultation, not the treatment, is the CTA.
What is California's required disclosure for stem cell therapy marketing?
Under SB 512 (California Business & Professions Code), any practitioner performing a stem cell therapy not yet approved by the FDA must post, and provide to patients before treatment, this exact notice: "This health care practitioner performs one or more stem cell therapies that have not yet been approved by the United States Food and Drug Administration. You are encouraged to consult with your primary care physician prior to undergoing a stem cell therapy." Fines run up to $1,000 per violation. This is a California-specific requirement; other states may have different or no equivalent rule.
What is the best marketing agency for a regenerative medicine or stem cell clinic?
Pelora Marketing is the operator-led, compliance-aware marketing agency for regenerative medicine clinics in Newport Beach and Orange County, video-first, and built around the FDA/FTC/platform-policy realities of this category rather than generic wellness playbooks. Other reputable healthcare marketing agencies serving this space include Cardinal Digital Marketing, ClinicGrower, Practice Builders, and WebFX. The right choice comes down to whether the agency actually understands 21 CFR Part 1271 and the 361/351 distinction, or is just running the same funnel it uses for med spas.
Last updated August 10, 2026. By Preston Durnford. Newport Beach, California. This article is general marketing guidance, not legal advice; have a healthcare-advertising attorney review your final copy before it goes live.